TRIPEP APPOINTS Mr JAN NILSSON AS NEW CEO
TRIPEP APPOINTS Mr JAN NILSSON AS NEW CEO The Board of Directors of Tripep AB (publ) has appointed Mr Jan Nilsson as the new CEO of TRIPEP AB as of the 1st of December, 2004. Mr Jan Nilsson is at present the CEO of Schering-Plough Sweden AB. His employment with Schering-Plough ends on November 30, 2004. Mr Jan Nilsson has more than 30 years of experience within the pharmaceutical industry and has since year 2000 been the CEO of Schering-Plough Sweden AB. Mr Jan Nilsson will replace Professor Anders Vahlne who has acted as CEO during the recruitment process. Professor Vahlne remains as Head of Research at Tripep. "We are proud that Mr Jan Nilsson has decided to join the Tripep team as our new CEO. Jans experience from big-pharma and including a vast experience of clinical trials is the best possible background we could ask for", says Tripep's chairman Rolf L. Nordström. "I look forward to joining Tripep at this very exciting moment in time with the clinical trials of Tripeps new HIV-1 inhibitor alphaHGA just around the corner. I think that my previous experience from big-pharma with drugs for treating chronic viral infections will be put to good use at Tripep", says Mr Jan Nilsson. For more information, please contact: Rolf Nordström, Chairman, Tripep AB Tel: +44 20 7839 8686, mobile phone: +44 7776 137 400 E-mail: rolf.l.nordstrom@btinternet.com Jan Nilsson, Mobile phone: +46 704-66 31 63 Anders Vahlne, CEO and Head of Research, Tripep AB Tel: +46 35 31755, mobile phone: +46 709-28 05 28 E-mail: anders.vahlne@labmed.ki.se Conor McCarthy, NCB, Dublin, Ireland Tel: +353 1 611 5989, mobile phone: +353 87 290 0409 E-mail: conor.mccarthy@ncb.ie Lisa Baderoon, Rebecca Skye Dietrich Buchanan Communications Tel: + 44 20 7466 5000, mobile phone: +44 7721 413 496 E-mail: lisab@buchanan.uk.com Tripep AB is a Swedish biotechnology research company that develops and commercialises candidate drugs based on patented technologies. Its main focuses are: -research and development of an HIV-inhibiting drug, -preclinical research focusing on the development of therapeutic and prophylactic vaccines against HIV and Hepatitis C, and -the RAS ® technology platform. For more details of the company's technologies, please refer to the company's web site at www.tripep.se ------------------------------------------------------------ This information was brought to you by Waymaker http://www.waymaker.net The following files are available for download: http://www.waymaker.net/bitonline/2004/11/05/20041105BIT20260/wkr0019.pdf